4
Changes in Ownership
Relay Therapeutics, Inc. Filed Acc 0000950170-25-011327
Chief Financial Officer sold 58,936 shares at an average $4.55 ($268,339)
- Chief Financial Officer acquired 139,141 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Catinazzo Thomas · Chief Financial Officer
Table I: Non-derivative
5 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-01-28 | Sale : show line 1 in the form 10b5-1 | −33,753 | $4.63 | $156,276 | 265,473 | D |
| 2025-01-28 | Sale : show line 2 in the form 10b5-1 | −2,283 | $4.63 | $10,570 | 263,190 | D |
| 2025-01-28 | Grant or award : show line 3 in the form 10b5-1 | +139,141 | 402,331 | D | ||
| 2025-01-29 | Sale : show line 4 in the form 10b5-1 | −2,109 | $4.55 | $9,596 | 400,222 | D |
| 2025-01-30 | Sale : show line 5 in the form 10b5-1 | −20,791 | $4.42 | $91,896 | 379,431 | D |
| Open-market sales · 58,936 sh · avg $4.55 · $268,339 | ||||||
Loading xslF345X05/ownership.xml…